ロード中...
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
BACKGROUND: Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis. This Phase 2a study tested efficacy (Hb response) and safety of roxadustat in anemic nondialysis-dependent chronic kidney disease (NDD-CKD) subjects. METHODS: NDD-CKD sub...
保存先:
| 出版年: | Nephrol Dial Transplant |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2015
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4569392/ https://ncbi.nlm.nih.gov/pubmed/26238121 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfv302 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|